Δευτέρα 12 Μαρτίου 2018

Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.

Related Articles

Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.

J Nat Prod. 2018 Mar 09;:

Authors: Nadaradjane C, Yang CH, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, Smith AB, Horwitz SB, McDaid HM

Abstract
(+)-Discodermolide is a microtubule-stabilizing agent with potential for the treatment of taxol-refractory malignancies. (+)-Discodermolide congeners containing the C-3'-phenyl side chain of taxol (paclitaxel) were synthesized based on computational docking models predicting this moiety would fill an aromatic pocket of β-tubulin insufficiently occupied by (+)-discodermolide, thereby conferring improved ligand-target interaction. It was recently demonstrated, however, that the C-3'-phenyl side chain occupied a different space, instead extending toward the M-loop of β-tubulin, where it induced a helical conformation, hypothesized to improve lateral contacts between adjacent microtubule protofilaments. This insight led us to evaluate the biological activity of hybrid congeners using a panel of genetically diverse cancer cell lines. Hybrid molecules retained the same tubulin-polymerizing profile as (+)-discodermolide. Since (+)-discodermolide is a potent inducer of accelerated senescence, a fate that contributes to drug resistance, congeners were also screened for senescence induction. Flow cytometric and transcriptional analysis revealed that the hybrids largely retained the senescence-inducing properties of (+)-discodermolide. In taxol-sensitive cell models, the congeners had improved dose-response parameters relative to (+)-discodermolide and, in some cases, were superior to taxol. However, in cells susceptible to senescence, EMax increased without concomitant improvements in EC50 such that overall dose-response profiles resembled that of (+)-discodermolide.

PMID: 29522336 [PubMed - as supplied by publisher]



from #ΓεύσηΌσφρηση via xlomafota13 on Inoreader http://ift.tt/2FMxIpJ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις